Vedolizumab Doesn't Increase Risk of C diff in Ulcerative Colitis

Vedolizumab's effects in the intestines have led to concerns that the antibody could increase the risk of C difficile infection in patients with ulcerative colitis.

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Sahil Khanna ,Jean Frederic Colombel ,Rahul Dalal ,Icahn School Of Medicine At Mount Sinai ,Shire Plc ,Center At Mount Sinai Hospital ,Inflammatory Bowel Diseases ,Mount Sinai Hospital ,Icahn School ,Mount Sinai ,Mayo Clinic ,Facile Therapeutics ,Ulcerative Colitis ,Inflammatory Bowel Disease ,Nflammatory Bowel Disease Ibd ,Bd ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Colectomy ,Colorectal Cancer ,Crohns Disease ,Immunomodulator ,Lenalidomide ,Abdominal Infection ,Anti Tnf ,Anti Tumor Necrosis Factor ,Gastrointestinal Infection ,Hi Infection ,Hospitals ,Inpatient Care ,Antibiotics ,Igecycline ,Corticosteroid ,Humanized Monoclona ,